Patients treated with EQW had a significantly greater reduction in A1c than those treated with exenetide b.i.d., (-1.9 vs -1.5% ... 6 study was designed to compare EQW head-to-head with liraglutide.

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and a portfolio of GLP-1 and amylin agonists in-licensed from China. The lead ...

The average American woman weighs about 170 pounds and stands about 5 feet, 4 inches tall. But it’s important to remember ...

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs ... to further assess and allow comparison of several GLP-1RA agents' impact on steady-state ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

The following is a summary of “Treatment of Hypothalamic Obesity With GLP-1 Analogs,” published in the November 2024 issue of Endocrinology by Dimitri and Roth. Damage to hypothalamic nuclei or ...

Tiziana’s nasal anti-CD3 therapy has been shown not only to enhance the positive effects of semaglutide, a GLP-1 agonist marketed by Novo Nordisk under the brand names Ozempic and Wegovy when ...

Tiziana’s nasal anti-CD3 therapy has been shown not only to enhance the positive effects of semaglutide, a GLP-1 agonist marketed by Novo Nordisk under the brand names Ozempic and Wegovy when ...